Premium
Overcoming obstacles in Parkinson's disease
Author(s) -
Sherer Todd B.,
Chowdhury Sohini,
Peabody Katherine,
Brooks Deborah W.
Publication year - 2012
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.25260
Subject(s) - prioritization , disease , transformative learning , drug development , context (archaeology) , parkinson's disease , medicine , intensive care medicine , risk analysis (engineering) , engineering ethics , psychology , drug , psychiatry , process management , pathology , business , engineering , paleontology , pedagogy , biology
Improved symptomatic and disease‐modifying treatments are needed for Parkinson's disease (PD). Although significant advances have been made in the understanding of PD etiology, the translation of these discoveries into novel transformative therapies has been limited as a result of systemic challenges in PD drug development. Preclinical testing lacks clear standards and prioritization criteria for advancing therapies to the clinic. Clinical testing is marked by expensive, long, and uninformative studies. In parallel to these scientific challenges, funding of late‐stage drug development has become increasingly scarce and risk averse. In this context, novel models of collaboration and funding are opening up new avenues for pursuing treatments. This review will discuss the most critical challenges in PD drug development and the innovative approaches being developed to overcome these hurdles. © 2012 Movement Disorder Society